sur Mainz BioMed N.V.
Mainz Biomed to Showcase Colorectal Cancer Screening Advances
Mainz Biomed N.V. will participate in the WEO CRC Screening Committee Meeting on October 3, 2025, in Berlin. The molecular genetics diagnostics company specializes in early cancer detection. Dr. Lena Krammes, a Senior Scientist at Mainz Biomed, will present research on RNA-based diagnostics at this global event.
The company's findings are part of the "Evaluation of New Tests" session. Key results from their eAArly DETECT study include 97% sensitivity and specificity for colorectal cancer detection. Additionally, they report 82% sensitivity for advanced adenomas and a 100% detection rate for adenomas with high-grade dysplasia.
Mainz Biomed's efforts support global colorectal cancer screening advancements. CEO Guido Baechler emphasizes the importance of their contributions to developing effective screening tools. The company continues to drive innovation in early cancer detection and prevention.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.